BG105128A - Therapeutic combinations of selective estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty - Google Patents
Therapeutic combinations of selective estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailtyInfo
- Publication number
- BG105128A BG105128A BG105128A BG10512801A BG105128A BG 105128 A BG105128 A BG 105128A BG 105128 A BG105128 A BG 105128A BG 10512801 A BG10512801 A BG 10512801A BG 105128 A BG105128 A BG 105128A
- Authority
- BG
- Bulgaria
- Prior art keywords
- ghs
- serm
- growth hormone
- compositions
- estrogen receptor
- Prior art date
Links
- 208000036119 Frailty Diseases 0.000 title abstract 2
- 206010003549 asthenia Diseases 0.000 title abstract 2
- 239000003324 growth hormone secretagogue Substances 0.000 title 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 title 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention is directed to pharmaceutical combination compositions and methods comprising (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8- tetrahydro-naphthalene-2-ol or a pharmaceutically acceptable salt thereof and 2-amino-N-(1(R)-(2,4-difluoro-benzyloxymethyl)-2-oxo-2-(3-oxo-3a(R) -pyridin-2-ylmethyl)-2-(2,2,2,-triflluoro-ethyl)-2,3,3a,4,6,7- hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-ethyl)-2-methyl-propionamide or a pharmaceutically acceptable salt thereof, method of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteroporotic fracture, low bone mass and low muscle mass. 29 claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8942498P | 1998-06-16 | 1998-06-16 | |
| PCT/IB1999/000796 WO1999065488A1 (en) | 1998-06-16 | 1999-05-03 | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG105128A true BG105128A (en) | 2001-11-30 |
Family
ID=22217565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105128A BG105128A (en) | 1998-06-16 | 2001-01-08 | Therapeutic combinations of selective estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1085867A1 (en) |
| JP (1) | JP2002518328A (en) |
| KR (1) | KR20010052817A (en) |
| CN (1) | CN1305378A (en) |
| AP (1) | AP9901581A0 (en) |
| AR (1) | AR018868A1 (en) |
| AU (1) | AU3342099A (en) |
| BG (1) | BG105128A (en) |
| BR (1) | BR9911357A (en) |
| CA (1) | CA2335112A1 (en) |
| CO (1) | CO5070586A1 (en) |
| EA (1) | EA200001189A1 (en) |
| GT (1) | GT199900083A (en) |
| HR (1) | HRP20000857A2 (en) |
| HU (1) | HUP0102395A2 (en) |
| ID (1) | ID26726A (en) |
| IL (1) | IL139587A0 (en) |
| IS (1) | IS5727A (en) |
| MA (1) | MA26648A1 (en) |
| NO (1) | NO20006381D0 (en) |
| OA (1) | OA11569A (en) |
| PA (1) | PA8472101A1 (en) |
| PE (1) | PE20000633A1 (en) |
| PL (1) | PL345064A1 (en) |
| SK (1) | SK18902000A3 (en) |
| TN (1) | TNSN99118A1 (en) |
| UY (1) | UY25557A1 (en) |
| WO (1) | WO1999065488A1 (en) |
| ZA (1) | ZA993973B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| AP2001002264A0 (en) | 2000-08-30 | 2001-09-30 | Pfizer Prod Inc | Sustained release formulations for growth hormone secretagogues. |
| US7524866B2 (en) | 2001-11-29 | 2009-04-28 | Gtx, Inc. | Prevention and treatment of androgen—deprivation induced osteoporosis |
| MXPA04005112A (en) * | 2001-11-29 | 2005-04-29 | Gtx Inc | Prevention and treatment of androgen-deprivation induced osteoporosis. |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| CU23558A1 (en) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE |
| KR20090107088A (en) | 2007-02-09 | 2009-10-12 | 트랜자임 파르마 인크 | Macrocyclic ghrelin receptor modulators and methods of using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA51676C2 (en) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (en) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | COMBINED THERAPY FOR OSTEOPOROSIS |
-
1999
- 1999-05-03 JP JP2000554368A patent/JP2002518328A/en active Pending
- 1999-05-03 PL PL99345064A patent/PL345064A1/en unknown
- 1999-05-03 KR KR1020007014140A patent/KR20010052817A/en not_active Ceased
- 1999-05-03 IL IL13958799A patent/IL139587A0/en unknown
- 1999-05-03 SK SK1890-2000A patent/SK18902000A3/en unknown
- 1999-05-03 BR BR9911357-0A patent/BR9911357A/en not_active Application Discontinuation
- 1999-05-03 HU HU0102395A patent/HUP0102395A2/en unknown
- 1999-05-03 CA CA002335112A patent/CA2335112A1/en not_active Abandoned
- 1999-05-03 WO PCT/IB1999/000796 patent/WO1999065488A1/en not_active Ceased
- 1999-05-03 EP EP99914723A patent/EP1085867A1/en not_active Withdrawn
- 1999-05-03 ID IDW20002604A patent/ID26726A/en unknown
- 1999-05-03 OA OA1200000346A patent/OA11569A/en unknown
- 1999-05-03 AU AU33420/99A patent/AU3342099A/en not_active Abandoned
- 1999-05-03 HR HR20000857A patent/HRP20000857A2/en not_active Application Discontinuation
- 1999-05-03 CN CN99807381A patent/CN1305378A/en active Pending
- 1999-05-03 EA EA200001189A patent/EA200001189A1/en unknown
- 1999-05-07 PA PA19998472101A patent/PA8472101A1/en unknown
- 1999-06-10 AP APAP/P/1999/001581A patent/AP9901581A0/en unknown
- 1999-06-11 PE PE1999000522A patent/PE20000633A1/en not_active Application Discontinuation
- 1999-06-11 UY UY25557A patent/UY25557A1/en not_active Application Discontinuation
- 1999-06-14 GT GT199900083A patent/GT199900083A/en unknown
- 1999-06-15 TN TNTNSN99118A patent/TNSN99118A1/en unknown
- 1999-06-15 ZA ZA9903973A patent/ZA993973B/en unknown
- 1999-06-15 AR ARP990102847A patent/AR018868A1/en not_active Application Discontinuation
- 1999-06-15 MA MA25622A patent/MA26648A1/en unknown
- 1999-06-16 CO CO99037624A patent/CO5070586A1/en unknown
-
2000
- 2000-11-24 IS IS5727A patent/IS5727A/en unknown
- 2000-12-14 NO NO20006381A patent/NO20006381D0/en not_active Application Discontinuation
-
2001
- 2001-01-08 BG BG105128A patent/BG105128A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PA8472101A1 (en) | 2000-09-29 |
| IS5727A (en) | 2000-11-24 |
| GT199900083A (en) | 2000-12-05 |
| CN1305378A (en) | 2001-07-25 |
| WO1999065488A1 (en) | 1999-12-23 |
| HRP20000857A2 (en) | 2001-10-31 |
| AP9901581A0 (en) | 1999-06-30 |
| ZA993973B (en) | 2000-12-15 |
| HUP0102395A2 (en) | 2001-11-28 |
| UY25557A1 (en) | 2001-01-31 |
| IL139587A0 (en) | 2002-02-10 |
| NO20006381L (en) | 2000-12-14 |
| SK18902000A3 (en) | 2001-12-03 |
| AU3342099A (en) | 2000-01-05 |
| AR018868A1 (en) | 2001-12-12 |
| EP1085867A1 (en) | 2001-03-28 |
| BR9911357A (en) | 2001-03-13 |
| PE20000633A1 (en) | 2000-07-26 |
| EA200001189A1 (en) | 2001-06-25 |
| MA26648A1 (en) | 2004-12-20 |
| OA11569A (en) | 2004-07-01 |
| PL345064A1 (en) | 2001-11-19 |
| JP2002518328A (en) | 2002-06-25 |
| TNSN99118A1 (en) | 2005-11-10 |
| CO5070586A1 (en) | 2001-08-28 |
| ID26726A (en) | 2001-02-01 |
| NO20006381D0 (en) | 2000-12-14 |
| CA2335112A1 (en) | 1999-12-23 |
| KR20010052817A (en) | 2001-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO1613B1 (en) | N-(3- hydroxy-4- piperidinyl) (dihydrobenzofuran, dihydro -2h- benzopyran or dihydrobenzodioxin) carboxamide derivatives | |
| EE04018B1 (en) | Thieno [2,3-d] pyrimidinediones, process for their preparation and pharmaceutical compositions containing them | |
| YU18400A (en) | Prostaglandin agonists and their use to treat bone disorders | |
| DE69827977D1 (en) | Spiro [1-azabicyclo [2.2.2] octane-3,2 '(3'H) -furo [2,3-b] pyridine for use in the treatment of psychotic and intellectual disorders | |
| WO1999021558A3 (en) | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | |
| WO2002060392A3 (en) | Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | |
| BG105128A (en) | Therapeutic combinations of selective estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty | |
| IL112957A0 (en) | Thieno [2,3-b] indoles, their preparation and pharmaceutical compositions containing them | |
| PL334228A1 (en) | Derivatives of pyrrolo[3,4-d]pyrimidinone and their application as drugs | |
| WO2001043733A3 (en) | Compositions, kits, apparatus, and methods for inhibiting cephalic inflammation | |
| Quattrone et al. | Decreased anticonvulsant activity of carbamazepine in 6-hydroxydopamine-treated rats | |
| BG105041A (en) | Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating muscaloskeletal frailty | |
| BG105125A (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone | |
| EP2140864A3 (en) | Use of GAL3 receptor antagonists for the treatment of depression and / or anxiety and compounds useful in such methods | |
| CA2274381A1 (en) | Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2 | |
| EP1099446A3 (en) | Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent | |
| ECSP993021A (en) | THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY | |
| PT1025101E (en) | NAFTO-IMIDAZONE-1,2,2-PYRIDINE DERIVATIVES ITS PREPARATION AND USE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM PERTURBACTIONS | |
| ECSP993020A (en) | COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY | |
| AU4448497A (en) | Novel 6 or 7 substituted analogues of swainsonine, processes for their preparation and their use as therapeutic agents | |
| TH57984A3 (en) | A therapeutic combination consisting of selective estrogen receptor modulators and parathyroid hormone. | |
| IL150405A0 (en) | BENZOISOTHIAZOLE SUBSTITUTED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN TREATING IL-8, GROα, GROβ, GROY AND NAP-2 MEDIATED DISEASES | |
| WO2004034967A3 (en) | 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety |